| General Information | |
|---|---|
| ZINC ID | ZINC000103211889 |
| Molecular Weight (Da) | 411 |
| SMILES | COC(=O)CCn1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1 |
| Molecular Formula | C18Cl3N3O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 103.067 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 26 |
| LogP | 5.673 |
| Activity (Ki) in nM | 2344.23 |
| Polar Surface Area (PSA) | 57.01 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.193 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.17 |
| Ilogp | 3.73 |
| Xlogp3 | 5.21 |
| Wlogp | 5.14 |
| Mlogp | 3.29 |
| Silicos-it log p | 5.05 |
| Consensus log p | 4.48 |
| Esol log s | -5.76 |
| Esol solubility (mg/ml) | 0.00072 |
| Esol solubility (mol/l) | 0.00000175 |
| Esol class | Moderately |
| Ali log s | -6.15 |
| Ali solubility (mg/ml) | 0.000288 |
| Ali solubility (mol/l) | 0.0000007 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.72 |
| Silicos-it solubility (mg/ml) | 0.00000786 |
| Silicos-it solubility (mol/l) | 1.91E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.11 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.19 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.997 |
| Logd | 4.11 |
| Logp | 4.954 |
| F (20%) | 0.002 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 98.85% |
| Vdss | 0.72 |
| Fu | 1.82% |
| Cyp1a2-inh | 0.967 |
| Cyp1a2-sub | 0.437 |
| Cyp2c19-inh | 0.949 |
| Cyp2c19-sub | 0.08 |
| Cl | 10.917 |
| T12 | 0.022 |
| H-ht | 0.153 |
| Dili | 0.984 |
| Roa | 0.585 |
| Fdamdd | 0.093 |
| Skinsen | 0.075 |
| Ec | 0.003 |
| Ei | 0.016 |
| Respiratory | 0.029 |
| Bcf | 3.115 |
| Igc50 | 4.78 |
| Lc50 | 6.513 |
| Lc50dm | 5.461 |
| Nr-ar | 0.011 |
| Nr-ar-lbd | 0.109 |
| Nr-ahr | 0.162 |
| Nr-aromatase | 0.258 |
| Nr-er | 0.501 |
| Nr-er-lbd | 0.06 |
| Nr-ppar-gamma | 0.179 |
| Sr-are | 0.836 |
| Sr-atad5 | 0.437 |
| Sr-hse | 0.008 |
| Sr-mmp | 0.319 |
| Sr-p53 | 0.832 |
| Vol | 366.691 |
| Dense | 1.115 |
| Flex | 0.333 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.547 |
| Synth | 2.358 |
| Fsp3 | 0.167 |
| Mce-18 | 18 |
| Natural product-likeness | -1.001 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |